Skip to content
GLP-1 Scorecard
Menu
Graded #352

Hers

Women-focused telehealth brand from Hims and Hers offering compounded semaglutide on a 6-month plan.

Visit HersWe may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Semaglutide
$199/mo (starting dose, compounded)
Tirzepatide
$299/mo (starting dose, plus a separate fee, brand-name)
Coverage
All 50 states
Brand-name
Yes

Weigh Hers against the full graded field on the best semaglutide providers scorecard, or line it up against its closest alternatives.

Factor breakdown

Each of the six graded dimensions. See the methodology.

Cost value54/100
Dose & formulation77/100
Clinical oversight55/100
Labs & monitoring52/100
Fulfillment81/100
Contract terms41/100

Strengths

  • Compounded GLP-1 access

Where it loses points

  • Limited public information on program details
  • FDA issued Hims & Hers Health, Inc. dba Hers a warning letter in September 2025; the letter is public in FDA's warning-letter database

Bottom line — Grade C

Best for: Shoppers who want mainstream telehealth GLP-1 access.

Ranked #352 of 544 on this scorecard. See our top-scoring pick, CoreAge Rx (#1), for comparison.

FDAWarning letter issued to Hims & Hers Health, Inc. dba Hers in September 2025. See the FDA warning-letter database.

Closest here

The rankings grading nearest Hers — the realistic shortlist.

The 20 rankings nearest this one

View full scorecard rankings →

Pricing/verification reflect Hers's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on Hers's site. Not medical advice; see our disclosure.

← Back to the scorecard